Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 5 , Pages 621-624 , May 2006

Less Is More: Inpatient Management of a Child With Complex Pharmacotherapy

,Accepted 19 December 2005.

REFERENCES 

  1. Blair J , Taggart B , Martin A . Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology . J Neural Transm . 2004;111:634–815
  2. Martin A , Van Hoof T , Stubbe D , Sherwin T , Scahill L . Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care . Psychiatr Serv . 2003;54:72–77
  3. Martin A , Young C , Leckman JF , Mukonoweshuro C , Rosenheck R , Leslie D . Age effects on antidepressant-induced manic conversion . Arch Pediatr Adolesc Med . 2004;158:773–780
  4. Prince J . Pharmacotherapy of attention-deficit hyperactivity disorder (ADHD) in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments . Child Adolesc Psychiatr Clin N Am . 2006;15:13–50
  5. Safer DJ . Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s . J Child Adolesc Psychopharmacol . 1997;7:265–274
  6. Turner S , Nunn AJ , Fielding K , Choonara I . Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study . Acta Paediatr . 1999;88:965–968
  7. University of Arizona Center for Education and Research on Therapeutics: QT Registry (2005), http://www.qtdrugs.org. Accessed December 22, 2005

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Kratochvil receives grant support from, is a consultant to, and/or member of the speakerapos;s bureau of Eli Lilly, Shire, Cephalon, Organon, AstraZeneca, and Pfizer. Dr. Varley is on speakerapos;s bureau of McNeil and Novartis and is a consultant to Shire Pharmaceuticals. Over the past 5 years, Dr. Martin has received honoraria and/or travel support from Eli Lilly and Janssen Pharmaceuticals. Dr. Cummins has no financial relationships to disclose.

PII: S0890-8567(09)61210-7

doi: 10.1097/01.chi.0000205707.78818.a6

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 45, Issue 5 , Pages 621-624 , May 2006

Article Tools